Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903242 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRCETPELANE | |
| SCHEMBL7917113 | 0.89 | CYP3A4 (0.59) | TSHRCETPCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL4948490 | 0.89 | CYP3A4 (0.59) | TSHRCETPCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL4948131 | 0.86 | CETP (0.63) | TSHRCETPCYP3A4 | |
| SCHEMBL4948692 | 0.86 | CETP (0.63) | TSHRCETPCYP3A4 | |
| SCHEMBL4948716 | 0.86 | CETP (0.63) | TSHRCETPCYP3A4 | |
| SCHEMBL4946336 | 0.86 | CETP (0.63) | TSHRCETPCYP3A4 | |
| SCHEMBL206609 | 0.86 | TSHR (0.68) | TSHRCETPELANEALDH1A1 | |
| SCHEMBL14051581 | 0.86 | MEN1 (0.45) | MEN1KMT2ATSHRCETPALDH1A1 | |
| SCHEMBL2365443 | 0.85 | TSHR (0.57) | TSHRCETPELANECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758515-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2010039474-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20080221070-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221070-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | SHBG, ESRRA, ESRRG | MEN1 1442/4885KMT2A 3881/4885TSHR 285/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | MEN1 68/4885KMT2A 3784/4885TSHR 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.